Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer

Lung Cancer

Volumn 72, Issue 2, 2011, Pages 219-223

  Rossman, Joanne ^a   Reddy, Vishnu ^b   Cantor, Alan ^c   Miley, Debi ^c   Robert, Francisco ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Chemotherapy; Small cell lung cancer

Indexed keywords

CARBOPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; IRINOTECAN; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, SMALL CELL; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; ENDONUCLEASES; ETOPOSIDE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS;

EID: 79953786810     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.08.023     Document Type: Article

References (24)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Govindan R., Page N., Morgenszten D., Read W., Tierney R., Vlahiotis A., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2006, 24:4539-4544.
3. Murray N., Turrisi A.T. A review of first-line treatment for small-cell lung cancer. J Thorac Oncol 2006, 1:270-278.
4. Roth B.J., Johnson D.H., Einhorn L.H., Schacter L.P., Cherng N.C., Cohen H.J., et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alteration of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992, 10:282-291.
5. Bonner J.A., Kozelsky T.F. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother Pharmacol 1996, 39:109-112.
6. Kim R., Hirabayashi N., Nishiyama M., Jinushi K., Toge T., Okada K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 1992, 50:760-766.
7. Noda K., Nishiwaki A., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346(2):85-91.
8. Hanna N.H., Bunn P.A., Langer C., Einhorn L., Guthrie T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients with previously untreated, extensive-stage (ES) disease small-cell lung cancer (SCLC). J Clin Oncol 2006, 24:2038-2043.
9. von Pawel J., Schiller J., Shepherd F., Fields S.Z., Kleisbauer J.P., Chrysson N.G., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658-667.
10. Rixe O., Ortuzar W., Alvarez M., Parker R., Reed E., Paull K., et al. Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996, 52:1855-1865.
11. Franciosi V., Barbieri R., Vasini G., Cacciani G.C., Capra R., Cuomo A., et al. A feasible combination of gemcitabine and oxaliplatin in patients with advanced non-small cell lung cancer. Preliminary results of a phase III study. Proc Am Soc Clin Oncol 2001, 20:263. [Abstract 2804].
12. Monnet I., Brienza S., Hugret F., Voisin S., Gastiaburu J., Saltiel J.C., et al. Association pour le traitemement des tumeurs intra thoraciques. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer. Eur J Cancer 1998, 34:1124-1127.
13. Raymond E., Faivre S., Woynarowski J.M., Chaney S.G. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998, 25:4-12.
14. Wasserman E., Cuvier C., Lokiec F., Goldwasser F., Kalla S., Mery-Mignard D., et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol 1999, 17:1751-1759.
15. Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., et al. A randomized, controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22:23-30.
16. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
17. Kaplan E.L., Meier P. Nonparametric observation for incomplete observation. J Am Stat Assoc 1958, 53:457-481.
18. Cox D.R. Regression models and life tables. J R Stat Soc 1972, 34:187-220.
19. Schiller J.H., Adak S., Cella D., DeVore R.F., Johnson D.H. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001, 19:2114-2122.
20. Horn L., Dahlberg S.E., Sandler A.B., Dowlati A., Moore D.F., Murren J.R., et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group E3501. J Clin Oncol 2009, 27:6006-6011.
21. Ready N., Dudek A.Z., Wang X.F., Graziano S., Green M.R., Vokes E.E. CALGB 303306: a phase II study of cisplatin, irinotecan and bevacizumab for untreated extensive-stage, small cell lung cancer. J Clin Oncol 2007, 25:400s. [Abstract 7563].
22. Olauseen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
23. Vilmar A.C., Santoni-Rugiu E., Sorensen J.B. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 2010, 21:1817-1824.
24. Skov B.C., Holm B., Erreboe A., Skov T., Mellemgaard A. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol 2010, 5:453-459.